

Meet The Professor: Optimizing the Management of Ovarian Cancer —
Part 3 of a 5-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What was the duration of treatment with olaparib and with niraparib in the Phase III SOLO-1 and PRIMA trials, respectively, evaluating those agents as maintenance therapy after debulking surgery and first-line platinum-based chemotherapy?**
 - Two years for both
 - Three years for both
 - Two years for olaparib, 3 years for niraparib
 - Two years for niraparib, 3 years for olaparib
- 2. In the Phase III PAOLA-1 study the addition of olaparib to bevacizumab as first-line maintenance therapy for advanced ovarian cancer resulted in an improvement in progression-free survival (PFS) in which of the following subgroups?**
 - Patients with tumor BRCA mutations
 - Patients without tumor BRCA mutations
 - Patients with homologous recombination deficiency (HRD)-positive tumors, including those with BRCA mutations
 - Patients with HRD-positive tumors without BRCA mutations
 - All of the above subgroups
- 3. The ongoing Phase III DUO-O trial is evaluating durvalumab with platinum-based chemotherapy and bevacizumab followed by which of the following maintenance regimens for patients with newly diagnosed advanced ovarian cancer?**
 - Durvalumab
 - Bevacizumab/niraparib
 - Durvalumab/ramucirumab/rucaparib
 - Durvalumab/bevacizumab/olaparib
- 4. Which of the following patients with advanced ovarian cancer derived the greatest PFS benefit in the Phase II OVARIO trial evaluating niraparib/bevacizumab after first-line bevacizumab/platinum chemotherapy?**
 - Those with homologous recombination-deficient (HRd) tumors
 - Those with homologous recombination-proficient (HRp) tumors
 - Outcomes were equivalent for patients with HRd and HRp tumors
- 5. Which of the following best describes the target of the novel antibody-drug conjugate upifitamab rilsodotin currently under investigation for patients with ovarian cancer?**
 - Folate receptor alpha
 - NaPi2b
 - Tissue factor
 - TROP2